DeepMed Research

Rogel Cancer Center: University of Michigan

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1991-01-01

Employees: -

Market Cap: -

Website: http://www.rogelcancercenter.org

Clinical Trials

Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations

Early Phase 1

Withdrawn

Conditions: Non-Small Cell Lung Cancer

Interventions: Radiation: PET-Adaptive RT
Drug: Erlotinib
Drug: Crizotinib

First Posted Date: 2014-10-29

Last Posted Date: 2016-06-24

Lead Sponsor: University of Michigan Rogel Cancer Center

Registration Number: NCT02277457

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas

Phase 2

Completed

Conditions: Lymphoma, T-Cell

Interventions: Drug: MLN9708

First Posted Date: 2014-06-09

Last Posted Date: 2017-11-13

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 13

Registration Number: NCT02158975

Locations: 🇺🇸
University of Michigan Hospital, Ann Arbor, Michigan, United States

Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies

Phase 1

Completed

Conditions: Hematologic Malignancies
Relapse
Graft-Versus-Host Disease

Interventions: Drug: Carfilzomib
Drug: Tacrolimus

First Posted Date: 2014-05-22

Last Posted Date: 2022-01-03

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 53

Registration Number: NCT02145403

Locations: 🇺🇸
University of Michigan Hospital, Ann Arbor, Michigan, United States

Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for Renal Cell Carcinoma

Not Applicable

Terminated

Conditions: Renal Cell Carcinoma

Interventions: Radiation: SBRT
Radiation: RFA

First Posted Date: 2014-05-14

Last Posted Date: 2017-11-07

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 4

Registration Number: NCT02138578

Locations: 🇺🇸
University of Michigan Hospital, Ann Arbor, Michigan, United States

Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery

Phase 2

Terminated

Conditions: Metastatic Melanoma
Brain Metastases

Interventions: Drug: Ipilimumab
Procedure: Stereotactic Radiosurgery

First Posted Date: 2014-03-27

Last Posted Date: 2021-05-12

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 4

Registration Number: NCT02097732

Locations: 🇺🇸
University of Michigan Hospital, Ann Arbor, Michigan, United States

A Randomized Comparative Study of a Weekly Versus Every Other Week Nurse Practitioner-led Symptom Management Clinic for Head and Neck Cancer Patients Undergoing Concurrent Chemotherapy and Radiation

Not Applicable

Withdrawn

Conditions: Head and Neck Cancer

Interventions: Other: Nurse Practitioner Clinic

First Posted Date: 2014-03-13

Last Posted Date: 2014-12-02

Lead Sponsor: University of Michigan Rogel Cancer Center

Registration Number: NCT02085525

Locations: 🇺🇸
University of Michigan Hospital, Ann Arbor, Michigan, United States

Early Assessment of Treatment Response Using Functional Diffusion Mapping

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Procedure: Diffusion MRI

First Posted Date: 2014-02-17

Last Posted Date: 2014-12-09

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 20

Registration Number: NCT02064283

Locations: 🇺🇸
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Ibrance
Drug: Bicalutamide
Drug: Zoladex
Drug: Lupron Depot

First Posted Date: 2014-02-11

Last Posted Date: 2020-09-16

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 72

Registration Number: NCT02059213

Locations: 🇺🇸
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Michigan Hospital, Ann Arbor, Michigan, United States

and more 5 locations

Optimization of MRI for Radiation Therapy

Completed

Conditions: Cancer Head &Neck
Cancer Pelvis
Cancer Liver
Cancer Brain

Interventions: Procedure: MRI Group

First Posted Date: 2014-01-24

Last Posted Date: 2025-01-14

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 250

Registration Number: NCT02045381

Locations: 🇺🇸
Univeristy of Michigan, Ann Arbor, Michigan, United States

Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas

Phase 1

Completed

Conditions: Adenocarcinoma of the Pancreas

Interventions: Drug: MK-1775
Drug: Gemcitabine
Radiation: Radiation Therapy

First Posted Date: 2014-01-15

Last Posted Date: 2020-02-17

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 34

Registration Number: NCT02037230

Locations: 🇺🇸
University of Michigan Hospital, Ann Arbor, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy